300122 Stock Overview
Chongqing Zhifei Biological Products Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Chongqing Zhifei Biological Products Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥28.16 |
| 52 Week High | CN¥61.68 |
| 52 Week Low | CN¥20.38 |
| Beta | 0.93 |
| 1 Month Change | -5.41% |
| 3 Month Change | 35.97% |
| 1 Year Change | -51.27% |
| 3 Year Change | -67.71% |
| 5 Year Change | -13.46% |
| Change since IPO | 338.29% |
Recent News & Updates
These 4 Measures Indicate That Chongqing Zhifei Biological Products (SZSE:300122) Is Using Debt Reasonably Well
Nov 26
Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Share Price Boosted 45% But Its Business Prospects Need A Lift Too
Sep 30Recent updates
These 4 Measures Indicate That Chongqing Zhifei Biological Products (SZSE:300122) Is Using Debt Reasonably Well
Nov 26Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Share Price Boosted 45% But Its Business Prospects Need A Lift Too
Sep 30Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) Analysts Are More Bearish Than They Used To Be
Sep 03Calculating The Fair Value Of Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122)
Aug 23We Think Chongqing Zhifei Biological Products (SZSE:300122) Can Stay On Top Of Its Debt
Jul 26Why Investors Shouldn't Be Surprised By Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Low P/E
May 21Earnings Miss: Chongqing Zhifei Biological Products Co., Ltd. Missed EPS By 35% And Analysts Are Revising Their Forecasts
Apr 26Is Chongqing Zhifei Biological Products (SZSE:300122) A Risky Investment?
Mar 26Shareholder Returns
| 300122 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -2.2% | -1.9% | -1.2% |
| 1Y | -51.3% | -16.2% | 11.8% |
Return vs Industry: 300122 underperformed the CN Biotechs industry which returned -16.2% over the past year.
Return vs Market: 300122 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 300122 volatility | |
|---|---|
| 300122 Average Weekly Movement | 11.8% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 300122's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 300122's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 7,365 | Rensheng Jiang | www.zhifeishengwu.com |
Chongqing Zhifei Biological Products Co., Ltd. engages in the research, development, manufacture, marketing, distribution, import, and export of vaccines and biological products in China. It also provides cold storage services.
Chongqing Zhifei Biological Products Co., Ltd. Fundamentals Summary
| 300122 fundamental statistics | |
|---|---|
| Market cap | CN¥67.41b |
| Earnings (TTM) | CN¥3.69b |
| Revenue (TTM) | CN¥36.43b |
18.3x
P/E Ratio1.9x
P/S RatioIs 300122 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300122 income statement (TTM) | |
|---|---|
| Revenue | CN¥36.43b |
| Cost of Revenue | CN¥27.41b |
| Gross Profit | CN¥9.02b |
| Other Expenses | CN¥5.33b |
| Earnings | CN¥3.69b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.54 |
| Gross Margin | 24.77% |
| Net Profit Margin | 10.13% |
| Debt/Equity Ratio | 28.8% |
How did 300122 perform over the long term?
See historical performance and comparisonDividends
2.8%
Current Dividend Yield52%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 01:50 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chongqing Zhifei Biological Products Co., Ltd. is covered by 27 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xin Zhang | AJ Securities Co., Ltd |
| Bo Li | BofA Global Research |
| Yuanrui Liu | Changjiang Securities Co. LTD. |